KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Tax Provisions (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Tax Provisions for 16 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 56.55% year-over-year to $19.4 million, compared with a TTM value of $133.6 million through Dec 2025, up 16.25%, and an annual FY2025 reading of $133.6 million, up 16.25% over the prior year.
  • Tax Provisions was $19.4 million for Q4 2025 at Biomarin Pharmaceutical, up from $4.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $57.3 million in Q2 2025 and bottomed at -$17.3 million in Q4 2022.
  • Average Tax Provisions over 5 years is $13.3 million, with a median of $6.5 million recorded in 2022.
  • The sharpest move saw Tax Provisions plummeted 99.5% in 2022, then skyrocketed 4364.89% in 2024.
  • Year by year, Tax Provisions stood at -$8.7 million in 2021, then tumbled by 99.5% to -$17.3 million in 2022, then skyrocketed by 93.95% to -$1.0 million in 2023, then surged by 4364.89% to $44.7 million in 2024, then crashed by 56.55% to $19.4 million in 2025.
  • Business Quant data shows Tax Provisions for BMRN at $19.4 million in Q4 2025, $4.4 million in Q3 2025, and $57.3 million in Q2 2025.